Tajikistan
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.06 (3.59 - 6.86) | 2015 | Modelled | WHO |
| 6.7 (5.60 - 8.60) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 7.2 (5.52 - 9.36) | 2013 | Modelled | Schweitzer et al, 2015 |
| 2.52 (2.11 - 2.89) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.88 (2.41 - 3.29) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.97 (2.46 - 3.45) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.06 (2.52 - 3.51) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.12 (2.53 - 3.59) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.17 (2.58 - 3.65) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.3 (2.67 - 3.79) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.80 - 3.97) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.59 (2.92 - 4.14) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.98 - 4.22) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.71 (3.04 - 4.28) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.8 (3.12 - 4.39) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.91 (3.25 - 4.52) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.01 (3.35 - 4.65) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.40 - 4.75) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.13 (3.45 - 4.77) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.24 (3.53 - 4.90) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.36 (3.60 - 5.03) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.47 (3.67 - 5.16) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.52 (3.71 - 5.23) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.55 (3.71 - 5.26) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.59 (3.74 - 5.32) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.63 (3.79 - 5.40) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.66 (3.80 - 5.46) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.67 (3.80 - 5.50) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.65 (3.80 - 5.46) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.63 (3.80 - 5.41) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.59 (3.75 - 5.36) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.55 (3.70 - 5.34) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.49 (3.62 - 5.32) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.77 (2.32 - 3.16) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.71 (0.43 - 1.17) | 2015 | Modelled | WHO |
| 0.29 (0.22 - 0.37) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.36 (0.27 - 0.46) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.30 - 0.50) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.32 - 0.54) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.43 (0.32 - 0.54) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.44 (0.32 - 0.55) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.33 - 0.57) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.35 - 0.60) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.5 (0.37 - 0.63) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.53 (0.40 - 0.68) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.56 (0.42 - 0.73) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.44 - 0.75) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.61 (0.46 - 0.77) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.48 - 0.81) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.68 (0.51 - 0.86) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.74 (0.55 - 0.94) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.06 (0.78 - 1.35) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.28 - 2.21) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.52 (1.84 - 3.22) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.2 (2.33 - 4.11) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.53 (2.54 - 4.60) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.61 (2.67 - 4.67) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.68 (2.76 - 4.73) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.74 (2.82 - 4.75) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (2.85 - 4.75) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.78 (2.87 - 4.78) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (2.84 - 4.76) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.72 (2.79 - 4.73) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.68 - 4.68) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.57 (2.57 - 4.62) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.41 - 4.59) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.18 (0.12 - 0.25) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 586,000 (487,000 - 754,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 239,197 (199,906 - 273,986) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 246,384 (206,301 - 281,557) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 250,969 (210,250 - 286,450) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 253,639 (209,711 - 293,940) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 255,681 (209,698 - 293,922) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 254,793 (206,309 - 292,900) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 253,850 (206,059 - 290,958) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 258,153 (207,765 - 295,266) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 264,217 (213,470 - 302,559) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 268,594 (218,045 - 308,930) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 267,841 (217,721 - 308,624) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 265,293 (217,563 - 306,590) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 265,983 (218,062 - 307,414) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 267,972 (220,754 - 309,072) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 269,227 (223,045 - 311,688) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 267,697 (222,851 - 312,158) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 266,353 (221,988 - 308,346) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 268,426 (223,059 - 310,170) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 271,647 (224,647 - 313,823) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 273,816 (224,871 - 316,004) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 272,728 (222,999 - 315,088) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 269,889 (220,750 - 312,624) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 267,829 (218,882 - 311,041) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 265,804 (217,502 - 309,966) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 263,171 (215,401 - 308,006) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 259,382 (212,079 - 305,117) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 254,534 (208,185 - 298,307) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 249,438 (205,186 - 291,110) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 243,659 (199,778 - 284,959) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 236,713 (192,666 - 278,781) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 228,845 (184,964 - 271,350) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 4.69 (3.29 - 6.48) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 6.58 (4.96 - 9.13) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.5 (4.94 - 8.84) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.61 (5.06 - 8.92) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.68 (5.17 - 8.91) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.13 (5.41 - 9.53) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.01 (5.44 - 9.32) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.86 (5.37 - 8.87) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.96 (5.42 - 9.14) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.84 (5.34 - 8.70) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.75 (5.29 - 8.54) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.72 (5.32 - 8.44) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.29 (4.97 - 7.86) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.56 (5.17 - 8.22) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.09 (4.85 - 7.65) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.1 (4.80 - 7.66) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.21 (4.88 - 7.84) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.19 (4.84 - 7.88) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.22 (4.82 - 7.91) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.29 (4.85 - 7.94) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.32 (4.86 - 8.01) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.44 (4.98 - 8.24) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.34 (4.88 - 7.99) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.92 (4.58 - 7.48) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.67 (3.56 - 6.05) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.31 (4.09 - 6.85) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.84 (3.71 - 6.26) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.82 (3.70 - 6.30) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.81 (3.57 - 6.40) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.74 (3.40 - 6.48) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.69 (3.29 - 6.48) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 637 | 2016 | Modelled | WHO |
| 353 (267 - 491) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 357 (271 - 485) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 370 (283 - 499) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 380 (294 - 507) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 412 (319 - 547) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 412 (313 - 551) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 415 (324 - 545) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 416 (325 - 538) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 422 (331 - 534) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 421 (328 - 535) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 427 (338 - 537) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 414 (327 - 517) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 424 (335 - 532) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 408 (325 - 512) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 417 (328 - 523) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 433 (340 - 546) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 452 (350 - 575) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 440 (344 - 560) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 480 (369 - 608) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 466 (360 - 590) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 504 (388 - 635) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 500 (386 - 640) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 481 (373 - 608) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 442 (340 - 569) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 406 (310 - 527) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 429 (329 - 561) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 412 (316 - 532) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 437 (325 - 582) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 441 (316 - 602) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 445 (313 - 615) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 445 (313 - 615) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 99 | 2019 | Survey/reported | WHO/UNICEF |
| 99 | 2018 | Survey/reported | WHO/UNICEF |
| 99 | 2017 | Survey/reported | WHO/UNICEF |
| 92 | 2016 | Survey/reported | WHO/UNICEF |
| 95 | 2015 | Survey/reported | WHO/UNICEF |
| 98 | 2014 | Survey/reported | WHO/UNICEF |
| 98 | 2013 | Survey/reported | WHO/UNICEF |
| 98 | 2012 | Survey/reported | WHO/UNICEF |
| 98 | 2011 | Survey/reported | WHO/UNICEF |
| 96 | 2010 | Survey/reported | WHO/UNICEF |
| 97 | 2009 | Survey/reported | WHO/UNICEF |
| 85 | 2008 | Survey/reported | WHO/UNICEF |
| 83 | 2007 | Survey/reported | WHO/UNICEF |
| 94 | 2006 | Survey/reported | WHO/UNICEF |
| 98 | 2005 | Survey/reported | WHO/UNICEF |
| 90 | 2004 | Survey/reported | WHO/UNICEF |
| 77 | 2003 | Survey/reported | WHO/UNICEF |
| 80 | 2002 | Survey/reported | WHO/UNICEF |
| 99 | 2020 | Survey/reported | WHO/UNICEF |
| 99 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 97 | 2019 | Survey/reported | WHO/UNICEF |
| 97 | 2020 | Survey/reported | WHO/UNICEF |
| 97 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 278 (188 - 414) | 2016 | Survey/reported | Larney S et al, 2017 |
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 4.09 (3.32 - 5.03) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.14 (3.35 - 5.13) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.15 (3.33 - 5.16) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.34 - 5.05) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.28 - 4.99) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.08 (3.30 - 5.01) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.33 - 5.05) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.15 (3.35 - 5.12) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.18 (3.37 - 5.15) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.19 (3.36 - 5.14) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.17 (3.37 - 5.10) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.14 (3.34 - 5.06) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.1 (3.31 - 5.04) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.27 - 5.01) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.05 (3.23 - 5.06) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.06 (3.24 - 5.02) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.09 (3.28 - 5.06) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.13 (3.32 - 5.09) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.16 (3.35 - 5.11) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.17 (3.35 - 5.13) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.14 (3.33 - 5.08) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.09 (3.31 - 5.02) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.04 (3.26 - 4.95) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4 (3.22 - 4.90) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.97 (3.21 - 4.89) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.96 (3.22 - 4.86) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.96 (3.21 - 4.84) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.97 (3.23 - 4.88) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.98 (3.24 - 4.88) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.99 (3.24 - 4.90) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.82 (3.08 - 4.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.88 (2.29 - 3.12) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.1 (1.10 - 6.70) | 2014 | Survey/reported | Gower et al, 2014 |
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 61.3 (56.80 - 65.60) | 2004 | Survey/reported | Beyrer C et al, 2009 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 203,657 (164,972 - 250,594) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 207,035 (168,714 - 256,062) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 210,400 (171,677 - 259,332) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 213,580 (173,541 - 262,122) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 216,877 (176,232 - 265,940) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 220,708 (179,016 - 272,031) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 225,633 (182,851 - 276,303) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 231,884 (187,787 - 285,221) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 238,711 (193,139 - 294,618) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 245,350 (198,024 - 302,460) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 251,124 (202,673 - 311,106) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 255,063 (205,949 - 315,316) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 257,377 (208,144 - 317,437) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 259,248 (208,664 - 320,402) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 261,830 (209,661 - 324,196) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 266,493 (213,094 - 330,670) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 273,235 (219,707 - 337,636) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 281,039 (226,520 - 343,707) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 289,458 (233,588 - 353,569) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 297,988 (240,588 - 363,975) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 306,072 (246,069 - 377,190) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 312,365 (251,727 - 383,824) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 316,973 (256,586 - 390,704) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 321,109 (260,077 - 395,074) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 325,977 (264,566 - 401,342) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 332,960 (269,022 - 409,150) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 343,264 (279,629 - 420,756) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 353,710 (284,566 - 439,897) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 360,532 (292,280 - 447,327) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 364,312 (294,434 - 448,247) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 362,287 (292,592 - 445,887) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 66,600 (52,900 - 72,300) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 6.05 (4.31 - 8.29) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.71 (2.89 - 4.77) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.76 (2.91 - 4.86) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.92 (3.04 - 5.14) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.02 (3.09 - 5.26) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.3 (3.23 - 5.63) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.29 (3.24 - 5.54) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.3 (3.29 - 5.58) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.37 (3.41 - 5.48) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.3 (3.38 - 5.45) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.38 (3.41 - 5.50) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.43 (3.49 - 5.57) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.41 (3.46 - 5.48) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.44 (3.49 - 5.52) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.39 (3.47 - 5.47) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.48 (3.51 - 5.62) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.61 (3.54 - 5.84) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.59 (3.49 - 5.91) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.64 (3.55 - 6.01) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.61 (3.54 - 5.98) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.67 (3.54 - 6.02) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.78 (3.70 - 6.22) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.94 (3.86 - 6.38) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.16 (4.05 - 6.61) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.39 (4.23 - 6.85) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.91 (4.61 - 7.59) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.68 (4.46 - 7.26) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.13 (4.74 - 7.90) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.07 (4.60 - 7.97) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.03 (4.47 - 8.01) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.05 (4.31 - 8.29) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 334 | 2016 | Modelled | WHO |
| 574 (409 - 787) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 574 (409 - 787) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 561 (415 - 744) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 553 (418 - 725) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 546 (422 - 703) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 514 (401 - 661) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 484 (380 - 618) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 448 (352 - 570) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 419 (329 - 537) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 392 (307 - 507) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 371 (287 - 483) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 355 (268 - 457) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 345 (264 - 446) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 335 (257 - 434) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 326 (248 - 420) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 321 (247 - 407) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 306 (240 - 384) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 294 (233 - 367) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 290 (228 - 361) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 287 (226 - 357) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 282 (222 - 354) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 274 (213 - 344) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 269 (210 - 337) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 261 (205 - 330) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 256 (196 - 333) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 252 (190 - 325) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 249 (187 - 325) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 229 (176 - 299) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 219 (170 - 288) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 206 (160 - 267) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 200 (155 - 256) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 278 (188 - 414) | 2016 | Survey/reported | Larney S et al, 2017 |
Number of 28-pill count bottles exported from Indian manufacturers (SOF-based regimens)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 565 | 2016 | Survey/reported | CHAI HCV Market Report |
| 621 | 2017 | Survey/reported | CHAI HCV Market Report |
| 1,598 | 2018 | Survey/reported | CHAI HCV Market Report |
| 1,712 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
Price of HCV cure (Lowest average FOB price for 3 months of pangenotypic regimens)
National
Download| Value (US $) | Year | Type | Source |
|---|---|---|---|
| 300 | 2016 | Survey/reported | CHAI HCV Market Report |
| 177 | 2017 | Survey/reported | CHAI HCV Market Report |
| 147 | 2018 | Survey/reported | CHAI HCV Market Report |
| 156 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
445
2019
(313 - 615)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
574
2019
(409 - 787)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.18
(%)
2020, latest modelled
(0.12 - 0.25(%))
WHO
Eligible for HBV generic medicines
Eligible for HCV generic medicines
